Search - tctmd.com

Displaying 441 - 460 of 1204

Sort: Relevancy | Date

Presentation THT 2022

Percutanous Mitral Valve Repair Devices (Mitral TEER vs Annuloplasty/Chordal Suspension)

Presenter: Mark Reisman

February 02, 2022

News Conference News STS 2022

Higher Mortality After MV Surgery in Poorer Communities: STS Database

Michael O'Riordan

February 02, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Conference News PCR London Valves 2021

MitraClip Cuts HF Hospitalizations in Real-World Registry: EXPAND

Shelley Wood

November 26, 2021

News Conference News PCR London Valves 2021

‘Reasonable’ Results With TMVR for Mitral Regurgitation: CHOICE-MI

Michael O'Riordan

November 25, 2021

News Conference News PCR London Valves 2021

Promising Early Results for TriClip in Tricuspid Regurgitation: bRIGHT Registry

Shelley Wood

November 24, 2021

News Conference News AHA 2021

Tricuspid Repair During Mitral Surgery Slows Disease Progression at 2 Years

Caitlin E. Cox

November 13, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Conference News TCT 2021

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

Yael L. Maxwell

November 06, 2021

Presentation TCT 2021

MR Case Presentation and Heart Team Discussion and Wrap-Up

Presenter: Anu Tunuguntla

November 05, 2021

Presentation TCT 2021

TCT 581: Transcutaneous Edge-to-Edge Mitral Valve Repair With Mitral Annular & Subvalvular Calcification

Presenter: Adithya Mathews

November 05, 2021

Presentation TCT 2021

Chordal Repair Approaches (Harpoon, Pipeline, Chordart, Neochord, CardioMech)

Presenter: Anita Asgar

November 05, 2021

Presentation TCT 2021

Leaflet Augmentation Technologies (Half-Moon, Polares, Dura-Sutra)

Presenter: Firas Zahr

November 05, 2021

Presentation TCT 2021

Annular Repair Strategies (Millipede, Carillon, Cardioband)

Presenter: Jason Rogers

November 05, 2021

Presentation TCT 2021

Limitations of TEER and Justification for Additional Transcatheter Repair Concepts

Presenter: Georg Nickenig

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Presenter: Ori Ben-Yehuda

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Presenter: Joanna Chikwe

November 05, 2021

Presentation TCT 2021

Pro: TEER Is the Optimal Therapy TODAY!

Presenter: Saibal Kar

November 05, 2021

Presentation TCT 2021

New Insights From COAPT

Presenter: Gregg Stone

November 05, 2021

Presentation TCT 2021

Emerging Data From the TVT and STS Mitral Registries

Presenter: Paul Sorajja

November 05, 2021

Advertisement

Percutanous Mitral Valve Repair Devices (Mitral TEER vs Annuloplasty/Chordal Suspension)

Higher Mortality After MV Surgery in Poorer Communities: STS Database

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

MitraClip Cuts HF Hospitalizations in Real-World Registry: EXPAND

‘Reasonable’ Results With TMVR for Mitral Regurgitation: CHOICE-MI

Promising Early Results for TriClip in Tricuspid Regurgitation: bRIGHT Registry

Tricuspid Repair During Mitral Surgery Slows Disease Progression at 2 Years

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

MR Case Presentation and Heart Team Discussion and Wrap-Up

TCT 581: Transcutaneous Edge-to-Edge Mitral Valve Repair With Mitral Annular & Subvalvular Calcification

Chordal Repair Approaches (Harpoon, Pipeline, Chordart, Neochord, CardioMech)

Leaflet Augmentation Technologies (Half-Moon, Polares, Dura-Sutra)

Annular Repair Strategies (Millipede, Carillon, Cardioband)

Limitations of TEER and Justification for Additional Transcatheter Repair Concepts

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Pro: TEER Is the Optimal Therapy TODAY!

New Insights From COAPT

Emerging Data From the TVT and STS Mitral Registries

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content